<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796055</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP177</org_study_id>
    <nct_id>NCT00796055</nct_id>
    <nct_alias>NCT00924235</nct_alias>
  </id_info>
  <brief_title>Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors</brief_title>
  <acronym>MEDI-547</acronym>
  <official_title>A Phase 1, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Relapsed or Refractory Solid Tumors Associated With EphA2 Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety, tolerability, and the highest dose of this drug given once every 3&#xD;
      weeks or once every week, (per 21 day cycle) in adult subjects with relapsed or refractory&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the safety, tolerability, and maximum tolerated dose (MTD) of MEDI 547 in a dose&#xD;
      escalation cohort for either administration schedule 1 dose every 3 weeks or 1 dose every&#xD;
      week in adult subjects with relapsed or refractory solid tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    MI-CP177 study closed per sponsor decision.&#xD;
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI-547 will be assessed based on the incidence of AEs, SAEs, laboratory abnormalities, physical examination changes, toxicities leading to permanent discontinuation of MEDI-547 and MEDI-547-related deaths.</measure>
    <time_frame>30 days after the last dose of MEDI-547.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The antitumor activity of MED-547 will be assessed based on objective response rate (ORR), time to response (TTR), duration of response (DR), time to progression (TTP), progression-free survival (PFS), and overall survival (OS).</measure>
    <time_frame>30 days after the last dose of MEDI-547</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-547</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-547</intervention_name>
    <description>Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For the dose-escalation cohort: cancer relapsed or refractory to at least 1 prior&#xD;
             standard care systemic regimen standard therapy with previous histological&#xD;
             confirmation of diagnosis of fallopian tube, primary peritoneal, endometrial,&#xD;
             cervical, prostate, non-small cell lung, esophageal, gastric, bladder, and renal cell&#xD;
             carcinomas or melanoma. Subjects with relapsed or refractory breast, epithelial&#xD;
             ovarian, or colon cancer with previous histological confirmation of diagnosis must&#xD;
             have progressed through more than 1 prior regimen of therapy. For patients enrolling&#xD;
             at the NCI, pathology must be confirmed by the Department of Pathology, CCR, NCI.&#xD;
&#xD;
          -  For the dose-expansion cohort: relapsed or refractory epithelial ovarian cancer with&#xD;
             progression through more than 1 prior regimen of therapy, or relapsed or refractory&#xD;
             fallopian tube, or primary peritoneal cancer with progression after at least 1 prior&#xD;
             standard care systemic regimen, with previous histological confirmation of cancer&#xD;
             diagnosis. For patients enrolling at the NCI, pathology must be confirmed by the&#xD;
             Department of Pathology, Center for Cancer Research (CCR), NCI.&#xD;
&#xD;
          -  Patients with the following histologic epithelial ovarian cancer cell types are&#xD;
             eligible: Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma,&#xD;
             undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma,&#xD;
             transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma not&#xD;
             otherwise specified (NOS).&#xD;
&#xD;
          -  For the dose-expansion cohort of subjects with relapsed or refractory ovarian cancer,&#xD;
             subjects must have an archival tumor sample that demonstrates EphA2 expression by&#xD;
             immunohistochemical stain.&#xD;
&#xD;
          -  Males or females at least 18 years of age at the time of obtaining informed consent.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test within 72&#xD;
             hours prior to MEDI-547 administration; and men and women of reproductive potential&#xD;
             must agree to practice an effective method of avoiding pregnancy (this is not to&#xD;
             include oral or implanted contraceptives (such as the &quot;pill&quot;, the &quot;patch&quot;, a Depo&#xD;
             Provera shot, or hormone laced intrauterine device, but allows the following: non&#xD;
             hormonal (copper), intrauterine device, female condom, diaphragm with spermicide,&#xD;
             cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual&#xD;
             partner) beginning at the time the ICF is signed, and must agree to continue using&#xD;
             such precautions while receiving MEDI-547 through 30 days after the last dose of&#xD;
             MEDI-547.&#xD;
&#xD;
          -  For the dose-escalation cohort: measurable disease by Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST) criteria is desirable but not required. The following are not&#xD;
             considered measurable: pleural effusion or ascites; osteoblastic/osteoclastic lesions&#xD;
             or evidence of disease on bone scan alone; progressive irradiated lesions alone, bone&#xD;
             marrow involvement, brain metastases, malignant hepatomegaly by physical exam alone;&#xD;
             or chemical markers (eg, CA-125, carcinoembryonic antigen [CEA], or prostate specific&#xD;
             antigen [PSA]). Recurrent disease following surgery or radiotherapy is measurable&#xD;
             provided that 30 days have elapsed since treatment and that measurable disease exists&#xD;
             outside the radiation port, or there is clear progression within the radiation port.&#xD;
&#xD;
          -  For the dose-expansion cohort: measurable disease, by RECIST criteria is required. The&#xD;
             following are not considered measurable: pleural effusion or ascites;&#xD;
             osteoblastic/osteoclastic lesions or evidence of disease on bone scan alone;&#xD;
             progressive irradiated lesions alone, bone marrow involvement, brain metastases,&#xD;
             malignant hepatomegaly by physical exam alone; or chemical markers (eg, CA-125, CEA,&#xD;
             or PSA). Recurrent disease following surgery or radiotherapy is measurable provided&#xD;
             that 30 days has elapsed since treatment and that measurable disease exists outside&#xD;
             the radiation port, or there is clear progression within the radiation port.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.&#xD;
&#xD;
          -  Life expectancy of greater than 16 weeks.&#xD;
&#xD;
          -  For subjects who had prior treatment with chemotherapy, biological therapy,&#xD;
             radiotherapy, or investigational therapy or had prior surgery: eligible for study&#xD;
             entry if at least 30 days have passed since their treatment/surgery, provided that all&#xD;
             toxicities related to prior treatment have resolved to ≤ Grade 1 severity by National&#xD;
             Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE&#xD;
             v3.0 and all surgical wounds have healed.&#xD;
&#xD;
          -  Prior immunotherapy with approved agents (eg, trastuzumab, cetuximab, panitumumab,&#xD;
             bevacizumab) is allowable if at least 30 days have passed.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ³ 1500/mm3, platelets ³ 100,000/mm3, hemoglobin &gt; 10.0&#xD;
             g/dL, serum creatinine greater than or equal to 1.5 times the upper limit of normal&#xD;
             [ULN] or calculated creatinine clearance &gt; 50 mL/min, serum bilirubin greater than or&#xD;
             equal to 2 times the ULN, alkaline phosphatase &lt; 3 times the ULN, and aspartate&#xD;
             transferase (AST) and alanine transferase (ALT) greater than or equal to 3 times the&#xD;
             ULN.&#xD;
&#xD;
          -  Prothrombin time (PT), partial thromboplastin time (PTT), and international normalized&#xD;
             ratio (INR) that are within normal institutional limits.&#xD;
&#xD;
          -  Written informed consent and Health Insurance Portability and Accountability Act&#xD;
             (HIPAA) authorization (applies to covered entities in the USA only) obtained from the&#xD;
             subject prior to receipt of any study medication or beginning study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  A history of central nervous system metastases or primary central nervous system&#xD;
             tumors.&#xD;
&#xD;
          -  Symptomatic pleural effusion or ascites requiring paracentesis.&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy of Grade 2 or greater.&#xD;
&#xD;
          -  Respiratory insufficiency requiring oxygen treatment, or lymphangitic involvement of&#xD;
             lungs.&#xD;
&#xD;
          -  Any evidence of hematemesis, melena, hematochezia, grade 2 or higher hemoptysis, or&#xD;
             gross hematuria. Patients with grade 1 hemoptysis or microscopic hematuria will be&#xD;
             permitted on study.&#xD;
&#xD;
          -  Active or recent history (within 3 months) of keratitis or conjunctivitis.&#xD;
&#xD;
          -  A history of significant adverse events related to a previously administered&#xD;
             monoclonal antibody.&#xD;
&#xD;
          -  A history of human immunodeficiency virus (HIV) or hepatitis virus infection&#xD;
             (HBV,HCV)will be excluded to eliminate the risk of increased adverse events due to&#xD;
             immune compromise or liver dysfunction.&#xD;
&#xD;
          -  Any evidence or history of myocardial infarction, angina, or arrhythmia (including&#xD;
             atrial fibrillation, multifocal premature ventricular contractions, ventricular&#xD;
             bigeminy or trigeminy, ventricular tachycardia or requirement for anti-arrhythmics&#xD;
             including digoxin), within 6 months prior to initiation of study drug.&#xD;
&#xD;
          -  Any evidence of uncontrolled hypertension (systolic blood pressure &gt; 150 mm Hg) within&#xD;
             3 months prior to initiation of investigational product.&#xD;
&#xD;
          -  Subjects currently on anticoagulant therapy for thromboembolic disorders or&#xD;
             prophylactic reasons will be excluded.&#xD;
&#xD;
          -  Any evidence of severe congestive heart failure with severity New York Heart&#xD;
             Association classification &gt; Class 1 within the past 12 weeks.&#xD;
&#xD;
          -  A marked baseline prolongation of QTc interval (eg, demonstration of QTc interval ≥&#xD;
             500 millisecs [ms]).&#xD;
&#xD;
          -  A prior stroke or transient ischemic attack (TIA) within 6 months prior to initiation&#xD;
             of (investigational product) MEDI-547.&#xD;
&#xD;
          -  Any evidence of an active infection or systemic use of antimicrobials within 72 hours&#xD;
             prior to initial treatment with MEDI-547.&#xD;
&#xD;
          -  Current or planned participation (from the day of study entry through 30 days after&#xD;
             the last dose of study drug) in a research protocol in which another investigational&#xD;
             agent or therapy may be administered.&#xD;
&#xD;
          -  Received another investigational agent within 30 days prior to initiation of study&#xD;
             drug or not fully recovered from prior investigational treatment.&#xD;
&#xD;
          -  A requirement for palliative chemotherapy, hormonal therapy, radiotherapy, surgery, or&#xD;
             immunotherapy during the course of the study.&#xD;
&#xD;
          -  For subjects in the dose-expansion cohort, history of prior malignancies within the&#xD;
             past 5 years other than non-melanomatous skin cancers that have been controlled,&#xD;
             carcinoma in situ of the cervix, or superficial bladder cancer.&#xD;
&#xD;
          -  A general medical or psychological condition or behavior, including substance&#xD;
             dependence or abuse that, in the opinion of the investigator, might not permit the&#xD;
             subject to complete the study or sign the informed consent.&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator would interfere with evaluation&#xD;
             of the investigational product or interpretation of study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherry Warwick</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <last_update_submitted>November 16, 2011</last_update_submitted>
  <last_update_submitted_qc>November 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

